Real world treatment patterns among patients with painful diabetic peripheral neuropathy in the United States
Nathaniel M Schuster, Sushanth Jeyakumar, Ann M Menzie, Moeen Panni, Nicole Princic, Meghan Moynihan, Charles E Argoff · 2026
Read Real world treatment patterns among patients with painful diabetic peripheral neuropathy in the United States by Nathaniel M Schuster, Sushanth Jeyakumar, Ann M Menzie, Moeen Panni, Nicole Princic, Meghan Moynihan, Charles E Argoff (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13537738.txt.
Description
Nathaniel Schuster and six co-authors charted how Americans actually take medicine for painful diabetic nerve damage, using insurance claims data, in this 2026 study. Guidelines exist, but real-world habits, doses, and staying power were less clear. The team followed nearly twenty-three thousand patients who started treatment between 2016 and 2023.
Almost everyone began with a single drug, most often gabapentin. Most patients on the leading drugs got doses below the advised level, and few ever raised them. More than half quit their first drug within three months, and about three quarters had quit within a year, with few switching to another. By the fourth round of treatment, most had stopped pain medicine entirely. The authors read this as a sign that current options fail many patients.
Catalog record
| CREATOR | Nathaniel M Schuster, Sushanth Jeyakumar, Ann M Menzie, Moeen Panni, Nicole Princic, Meghan Moynihan, Charles E Argoff |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |